As of the latest Form 4 filed Jul 10, 2026.
What Bicara Therapeutics Inc. Common Stock insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 66 most recent filings for BCAX.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-07-10 | 2026-07-09 | Cohlhepp Ryan President and COO | SSale | −536.00 | $29.00 | $15.5K | Yes (planned) | Form 4 ↗ |
| 2026-07-10 | 2026-07-08 | Cohlhepp Ryan, President and COO | SSale | −1.07K | $30.35 | $32.6K | Yes (planned) | Form 4 ↗ |
| 2026-07-10 | 2026-07-08 | Cohlhepp Ryan, President and COO | SSale | −4.31K | $29.80 | $128K | Yes (planned) | Form 4 ↗ |
| 2026-07-10 | 2026-07-08 | Cohlhepp Ryan, President and COO | SSale | −22.8K | $28.76 | $657K | Yes (planned) | Form 4 ↗ |
| 2026-07-10 | 2026-07-08 | Cohlhepp Ryan, President and COO | MExercise | +18.8K | $3.79 | $71.1K | Yes (planned) | Form 4 ↗ |
| 2026-07-10 | 2026-07-08 | Hyep Ivan Chief Financial Officer | SSale | −830.00 | $30.31 | $25.2K | Yes (planned) | Form 4 ↗ |
| 2026-07-10 | 2026-07-08 | Hyep Ivan, Chief Financial Officer | SSale | −4.41K | $29.82 | $132K | Yes (planned) | Form 4 ↗ |
| 2026-07-10 | 2026-07-08 | Hyep Ivan, Chief Financial Officer | SSale | −22.8K | $28.60 | $651K | Yes (planned) | Form 4 ↗ |
| 2026-07-10 | 2026-07-08 | Hyep Ivan, Chief Financial Officer | MExercise | +12.5K | $3.79 | $47.4K | Yes (planned) | Form 4 ↗ |
| 2026-05-26 | 2026-05-21 | Hyep Ivan Chief Financial Officer | SSale | −9.20K | $20.42 | $188K | Yes (planned) | Form 4 ↗ |
| 2026-05-26 | 2026-05-21 | Hyep Ivan, Chief Financial Officer | MExercise | +9.20K | $3.79 | $34.9K | Yes (planned) | Form 4 ↗ |
| 2026-05-20 | 2026-05-18 | Mazumdar Claire Chief Executive Officer | SSale | −2.98K | $20.35 | $60.6K | Yes (planned) | Form 4 ↗ |
| 2026-05-20 | 2026-05-18 | Mazumdar Claire, Chief Executive Officer | SSale | −12.0K | $19.96 | $240K | Yes (planned) | Form 4 ↗ |
| 2026-05-20 | 2026-05-18 | Mazumdar Claire, Chief Executive Officer | MExercise | +15.0K | $3.79 | $56.8K | Yes (planned) | Form 4 ↗ |
| 2026-05-18 | 2026-05-15 | Cohlhepp Ryan President and COO | SSale | −4.50K | $20.29 | $91.3K | Yes (planned) | Form 4 ↗ |
| 2026-05-18 | 2026-05-15 | Cohlhepp Ryan, President and COO | SSale | −8.00K | $20.29 | $162K | Yes (planned) | Form 4 ↗ |
| 2026-05-18 | 2026-05-15 | Cohlhepp Ryan, President and COO | MExercise | +8.00K | $3.79 | $30.3K | Yes (planned) | Form 4 ↗ |
| 2026-04-28 | 2026-04-27 | Raben David Chief Medical Officer | SSale | −5.50K | $22.88 | $126K | Yes (planned) | Form 4 ↗ |
| 2026-04-28 | 2026-04-27 | Raben David, Chief Medical Officer | MExercise | +5.50K | $3.79 | $20.8K | Yes (planned) | Form 4 ↗ |
| 2026-04-22 | 2026-04-21 | Hyep Ivan Chief Financial Officer | SSale | −9.20K | $23.00 | $212K | Yes (planned) | Form 4 ↗ |
| 2026-04-22 | 2026-04-21 | Hyep Ivan, Chief Financial Officer | MExercise | +9.20K | $3.79 | $34.9K | Yes (planned) | Form 4 ↗ |
| 2026-04-20 | 2026-04-20 | Mazumdar Claire Chief Executive Officer | SSale | −15.0K | $23.61 | $354K | Yes (planned) | Form 4 ↗ |
| 2026-04-20 | 2026-04-20 | Mazumdar Claire, Chief Executive Officer | MExercise | +15.0K | $3.79 | $56.8K | Yes (planned) | Form 4 ↗ |
| 2026-04-20 | 2026-04-16 | Mazumdar Claire, Chief Executive Officer | MExercise | +7.08K | $5.45 | $38.6K | Yes (planned) | Form 4 ↗ |
| 2026-04-20 | 2026-04-16 | Mazumdar Claire, Chief Executive Officer | MExercise | +7.45K | $3.79 | $28.2K | Yes (planned) | Form 4 ↗ |
| 2026-04-20 | 2026-04-16 | Mazumdar Claire, Chief Executive Officer | MExercise | +8.23K | $4.44 | $36.5K | Yes (planned) | Form 4 ↗ |
| 2026-04-17 | 2026-04-15 | Cohlhepp Ryan President and COO | SSale | −4.50K | $23.01 | $104K | Yes (planned) | Form 4 ↗ |
| 2026-04-17 | 2026-04-15 | Cohlhepp Ryan, President and COO | SSale | −8.00K | $23.01 | $184K | Yes (planned) | Form 4 ↗ |
| 2026-04-17 | 2026-04-15 | Cohlhepp Ryan, President and COO | MExercise | +8.00K | $3.79 | $30.3K | Yes (planned) | Form 4 ↗ |
| 2026-03-26 | 2026-03-25 | Raben David Chief Medical Officer | SSale | −5.50K | $18.95 | $104K | Yes (planned) | Form 4 ↗ |
| 2026-03-26 | 2026-03-25 | Raben David, Chief Medical Officer | MExercise | +5.50K | $3.79 | $20.8K | Yes (planned) | Form 4 ↗ |
| 2026-03-24 | 2026-03-23 | Hyep Ivan Chief Financial Officer | SSale | −9.20K | $18.52 | $170K | Yes (planned) | Form 4 ↗ |
| 2026-03-24 | 2026-03-23 | Hyep Ivan, Chief Financial Officer | MExercise | +9.20K | $3.79 | $34.9K | Yes (planned) | Form 4 ↗ |
| 2026-03-20 | 2026-03-20 | Mazumdar Claire Chief Executive Officer | SSale | −1.60K | $18.95 | $30.2K | Yes (planned) | Form 4 ↗ |
| 2026-03-20 | 2026-03-20 | Mazumdar Claire, Chief Executive Officer | MExercise | +1.60K | $3.79 | $6.05K | Yes (planned) | Form 4 ↗ |
| 2026-03-20 | 2026-03-19 | Mazumdar Claire, Chief Executive Officer | SSale | −6.91K | $18.78 | $130K | Yes (planned) | Form 4 ↗ |
| 2026-03-20 | 2026-03-19 | Mazumdar Claire, Chief Executive Officer | MExercise | +6.91K | $3.79 | $26.2K | Yes (planned) | Form 4 ↗ |
| 2026-03-20 | 2026-03-18 | Mazumdar Claire, Chief Executive Officer | SSale | −6.50K | $18.84 | $122K | Yes (planned) | Form 4 ↗ |
| 2026-03-20 | 2026-03-18 | Mazumdar Claire, Chief Executive Officer | MExercise | +6.50K | $3.79 | $24.6K | Yes (planned) | Form 4 ↗ |
| 2026-03-17 | 2026-03-16 | Cohlhepp Ryan President and COO | SSale | −4.50K | $19.66 | $88.5K | Yes (planned) | Form 4 ↗ |
| 2026-03-17 | 2026-03-16 | Cohlhepp Ryan, President and COO | SSale | −8.00K | $19.66 | $157K | Yes (planned) | Form 4 ↗ |
| 2026-03-17 | 2026-03-16 | Cohlhepp Ryan, President and COO | MExercise | +8.00K | $3.79 | $30.3K | Yes (planned) | Form 4 ↗ |
| 2026-03-11 | 2026-03-09 | Mazumdar Claire Chief Executive Officer | SSale | −36.8K | $19.17 | $705K | Yes (planned) | Form 4 ↗ |
| 2026-03-11 | 2026-03-09 | Mazumdar Claire, Chief Executive Officer | MExercise | +36.8K | $3.79 | $139K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-06 | Mazumdar Claire Chief Executive Officer | SSale | −3.82K | $18.75 | $71.6K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-06 | Mazumdar Claire, Chief Executive Officer | MExercise | +3.82K | $3.79 | $14.5K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-05 | Mazumdar Claire, Chief Executive Officer | SSale | −1.79K | $18.74 | $33.5K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-05 | Mazumdar Claire, Chief Executive Officer | MExercise | +1.79K | $3.79 | $6.77K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Mazumdar Claire, Chief Executive Officer | SSale | −2.63K | $18.73 | $49.3K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Mazumdar Claire, Chief Executive Officer | MExercise | +2.63K | $3.79 | $9.97K | Yes (planned) | Form 4 ↗ |
| 2026-03-05 | 2026-03-04 | Hyep Ivan Chief Financial Officer | SSale | −2.96K | $18.25 | $54.1K | Yes (planned) | Form 4 ↗ |
| 2026-03-05 | 2026-03-04 | Hyep Ivan, Chief Financial Officer | MExercise | +2.96K | $3.79 | $11.2K | Yes (planned) | Form 4 ↗ |
| 2026-03-05 | 2026-03-04 | Raben David Chief Medical Officer | SSale | −16.3K | $18.52 | $302K | Yes (planned) | Form 4 ↗ |
| 2026-03-05 | 2026-03-04 | Raben David, Chief Medical Officer | MExercise | +16.3K | $3.79 | $61.8K | Yes (planned) | Form 4 ↗ |
| 2026-03-05 | 2026-03-03 | Cohlhepp Ryan President and COO | SSale | −4.50K | $18.16 | $81.7K | Yes (planned) | Form 4 ↗ |
| 2026-03-05 | 2026-03-03 | Cohlhepp Ryan, President and COO | SSale | −12.9K | $18.16 | $234K | Yes (planned) | Form 4 ↗ |
| 2026-03-05 | 2026-03-03 | Cohlhepp Ryan, President and COO | MExercise | +12.9K | $3.79 | $48.9K | Yes (planned) | Form 4 ↗ |
| 2026-03-05 | 2026-03-03 | Hyep Ivan Chief Financial Officer | SSale | −13.6K | $18.22 | $247K | Yes (planned) | Form 4 ↗ |
| 2026-03-05 | 2026-03-03 | Hyep Ivan, Chief Financial Officer | MExercise | +6.24K | $3.79 | $23.6K | Yes (planned) | Form 4 ↗ |
| 2026-03-05 | 2026-03-03 | Hyep Ivan, Chief Financial Officer | MExercise | +7.32K | $3.79 | $27.7K | Yes (planned) | Form 4 ↗ |
| 2026-03-05 | 2026-03-03 | Raben David Chief Medical Officer | SSale | −200.00 | $18.45 | $3.69K | Yes (planned) | Form 4 ↗ |
| 2026-03-05 | 2026-03-03 | Raben David, Chief Medical Officer | MExercise | +200.00 | $3.79 | $757.96 | Yes (planned) | Form 4 ↗ |
| 2026-03-02 | 2026-02-26 | RA CAPITAL MANAGEMENT, L.P. Director | PPurchase | +300K | $16.00 | $4.80M | No | Form 4 ↗ |
| 2026-02-27 | 2026-02-25 | Cohlhepp Ryan President and COO | SSale | −523.00 | $18.04 | $9.43K | Yes (planned) | Form 4 ↗ |
| 2026-02-27 | 2026-02-25 | Cohlhepp Ryan, President and COO | SSale | −3.11K | $18.04 | $56.1K | Yes (planned) | Form 4 ↗ |
| 2026-02-27 | 2026-02-25 | Cohlhepp Ryan, President and COO | MExercise | +3.11K | $3.79 | $11.8K | Yes (planned) | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also BCAX’s full analysis or the market-wide insider trading feed. The tabs above jump to BCAX’s other SEC data.
Source: SEC Form 4 filings for BCAX, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.